Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 5% After Insider Selling

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares dropped 5% during mid-day trading on Friday after an insider sold shares in the company. The stock traded as low as $3.54 and last traded at $3.5350. Approximately 3,552,628 shares changed hands during mid-day trading, a decline of 83% from the average daily volume of 21,216,084 shares. The stock had previously closed at $3.72.

Specifically, CFO Ben R. Taylor sold 13,426 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $3.08, for a total transaction of $41,352.08. Following the transaction, the chief financial officer owned 1,195,349 shares of the company’s stock, valued at $3,681,674.92. This trade represents a 1.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Analyst Upgrades and Downgrades

RXRX has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday, January 22nd. JPMorgan Chase & Co. upgraded Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $10.00 to $11.00 in a research note on Wednesday, December 17th. UBS Group set a $11.00 target price on Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Finally, Morgan Stanley set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Wednesday, December 17th. Two analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Recursion Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $9.40.

Recursion Pharmaceuticals Price Performance

The firm has a 50 day moving average price of $4.27 and a two-hundred day moving average price of $4.78. The company has a market cap of $1.85 billion, a P/E ratio of -1.96 and a beta of 0.95. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.60 and a current ratio of 4.60.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in RXRX. TD Waterhouse Canada Inc. raised its position in shares of Recursion Pharmaceuticals by 64.1% in the second quarter. TD Waterhouse Canada Inc. now owns 5,631 shares of the company’s stock valued at $29,000 after purchasing an additional 2,200 shares during the period. International Assets Investment Management LLC bought a new position in Recursion Pharmaceuticals in the 4th quarter worth approximately $31,000. Sequoia Financial Advisors LLC purchased a new position in Recursion Pharmaceuticals in the 4th quarter valued at approximately $41,000. Caitong International Asset Management Co. Ltd grew its stake in Recursion Pharmaceuticals by 97.2% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 9,019 shares of the company’s stock valued at $46,000 after buying an additional 4,446 shares in the last quarter. Finally, Allworth Financial LP raised its holdings in Recursion Pharmaceuticals by 85.6% during the 3rd quarter. Allworth Financial LP now owns 9,548 shares of the company’s stock valued at $47,000 after acquiring an additional 4,403 shares during the period. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.